MOLMED (EGFF)

The Project will finance the RDI activities of the Promoter to develop innovative anti-cancer and rare diseases treatments in the field of cell and gene therapy, during the investment period 2019-2022.

The proposed transaction will accelerate the Promoter's RDI activities in the strategic and innovative scientific field of gene therapy. By co-investing in the project, the Bank contributes to the advancement in the field of anti-cancer and treatments for rare diseases, whilst also fostering the generation of European knowledge and acumen.

The project mainly concerns activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU, amending Directive 2011/92/EU. Nevertheless, the Bank's services will review during the project appraisal whether any of the investments require an EIA, as well as any other environmental details of the project.

The promoter has been assessed by EIB as being a listed company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2014/24/EU), then the Bank would require the promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/24/EU and Directive 89/665/EEC), with publication of tender notices in the EU Official Journal, as and where required.

Considering Molmed is a listed Company, publication and communication of the Project (among others, on website) can be performed only when the Finance Contract is signed.